Double maintains 1 strategies that include VTYX - Ventyx Biosciences, Inc.
Yahoo
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) --
Yahoo
Key Insights Given the large stake in the stock by institutions, Ventyx Biosciences' stock price might be vulnerable to...
Yahoo
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-rec
Yahoo
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors in H2VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: V
Yahoo
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patien
Yahoo
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: We
Current Value
$1.441 Year Return
Current Value
$1.441 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTG | -0.01% | $1.89B | 0.07% |
AGZ | -0.03% | $608.43M | 0.2% |
XBIL | -0.10% | $778.12M | 0.15% |
VGSH | -0.11% | $22.36B | 0.03% |
BILS | -0.12% | $3.95B | 0.1356% |
GSG | -0.21% | $896.58M | 0.75% |
COMT | -0.22% | $596.02M | 0.48% |
XONE | -0.23% | $608.48M | 0.03% |
TYA | -0.26% | $150.60M | 0.15% |
FMHI | -0.37% | $762.95M | 0.7% |
FXC | 0.47% | $87.31M | 0.4% |
AGZD | -0.56% | $109.53M | 0.23% |
FXY | 0.63% | $850.17M | 0.4% |
KRBN | -0.69% | $159.67M | 0.85% |
IBTI | 0.69% | $1.00B | 0.07% |
IBTK | 0.70% | $434.50M | 0.07% |
SCHR | 0.70% | $10.56B | 0.03% |
FLGV | 0.83% | $978.56M | 0.09% |
DBO | 0.86% | $178.84M | 0.77% |
IBTO | 0.94% | $338.77M | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 48.55% | $4.85B | 0.35% |
IWC | 44.84% | $772.99M | 0.6% |
GNOM | 44.21% | $39.83M | 0.5% |
ARKG | 43.20% | $914.43M | 0.75% |
IWO | 42.33% | $11.31B | 0.24% |
IWM | 41.00% | $63.66B | 0.19% |
VTWO | 40.87% | $12.07B | 0.07% |
IBB | 39.99% | $5.17B | 0.45% |
PTH | 39.98% | $98.02M | 0.6% |
CPRJ | 39.61% | $48.36M | 0.69% |
SCHA | 39.30% | $16.85B | 0.04% |
KOMP | 39.08% | $2.17B | 0.2% |
GSSC | 38.99% | $536.87M | 0.2% |
ARKX | 38.66% | $290.26M | 0.75% |
IWN | 38.44% | $11.00B | 0.24% |
ICVT | 38.38% | $2.46B | 0.2% |
ISCG | 38.19% | $643.26M | 0.06% |
NUSC | 38.09% | $1.14B | 0.31% |
KJUL | 37.99% | $113.06M | 0.79% |
PINK | 37.96% | $129.38M | 0.5% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -24.88% | $140.64M | 0.59% |
BTAL | -24.80% | $361.71M | 1.43% |
VIXY | -23.41% | $116.60M | 0.85% |
TPMN | -13.81% | $31.59M | 0.65% |
CORN | -10.87% | $49.32M | 0.2% |
USDU | -9.10% | $173.33M | 0.5% |
FTSD | -8.25% | $212.61M | 0.25% |
WEAT | -6.46% | $118.73M | 0.28% |
UUP | -6.43% | $279.52M | 0.77% |
UNG | -6.30% | $335.18M | 1.06% |
UGA | -6.29% | $72.41M | 0.97% |
DBE | -6.12% | $46.44M | 0.77% |
JUCY | -5.38% | $299.52M | 0.6% |
TFLO | -5.37% | $7.02B | 0.15% |
SOYB | -4.07% | $25.00M | 0.22% |
GBIL | -4.05% | $6.16B | 0.12% |
CARY | -3.80% | $347.36M | 0.8% |
ULST | -3.62% | $632.05M | 0.2% |
TAXF | -3.14% | $496.10M | 0.29% |
MMIN | -2.84% | $471.84M | 0.3% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMNM | 44.75% | $696.97M | -41.96% | 0.00% |
SYRE | 43.77% | $898.06M | -59.64% | 0.00% |
KYMR | 43.37% | $1.97B | -16.13% | 0.00% |
OCUL | 41.36% | $1.20B | +19.40% | 0.00% |
EYPT | 41.23% | $419.75M | -49.75% | 0.00% |
CMPS | 40.87% | $403.89M | -45.08% | 0.00% |
FDMT | 40.81% | $176.03M | -85.38% | 0.00% |
ABUS | 40.22% | $599.48M | +1.95% | 0.00% |
BHVN | 39.78% | $1.61B | -59.94% | 0.00% |
ARCT | 39.76% | $325.18M | -60.69% | 0.00% |
RGNX | 39.65% | $491.07M | -38.31% | 0.00% |
RCKT | 39.53% | $694.91M | -71.75% | 0.00% |
AGIO | 38.96% | $1.73B | -10.09% | 0.00% |
BEAM | 38.80% | $1.78B | -28.93% | 0.00% |
CATX | 38.62% | $202.64M | -83.25% | 0.00% |
KOD | 38.59% | $195.75M | +13.80% | 0.00% |
RXRX | 38.39% | $1.83B | -53.89% | 0.00% |
URI | 38.31% | $47.06B | +3.26% | 0.95% |
QTRX | 38.24% | $189.10M | -71.72% | 0.00% |
SITE | 38.23% | $5.53B | -19.71% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -18.36% | $22.07M | -71.93% | 0.00% |
CODX | -8.21% | $9.61M | -74.08% | 0.00% |
CNK | -6.97% | $3.64B | +79.07% | 0.25% |
QXO | -5.89% | $9.08B | -83.77% | 0.00% |
CHD | -5.09% | $23.64B | -9.90% | 1.20% |
GFI | -4.71% | $19.05B | +26.67% | 2.57% |
CL | -4.54% | $74.35B | -2.81% | 2.19% |
CBOE | -4.07% | $23.50B | +22.83% | 1.09% |
NOC | -3.75% | $67.81B | +0.46% | 1.75% |
K | -3.57% | $28.59B | +32.73% | 2.75% |
MVO | -3.49% | $67.97M | -37.26% | 21.16% |
STG | -3.47% | $28.09M | -38.64% | 0.00% |
PEP | -3.24% | $180.69B | -26.91% | 4.11% |
CNX | -3.18% | $4.70B | +32.44% | 0.00% |
MKTX | -3.16% | $8.23B | +1.72% | 1.35% |
NEUE | -2.95% | $61.07M | +15.93% | 0.00% |
PG | -2.93% | $386.31B | -1.52% | 2.47% |
CME | -2.29% | $100.16B | +31.56% | 3.79% |
STNG | -1.96% | $2.12B | -49.56% | 3.85% |
MSIF | -1.75% | $753.44M | +35.28% | 6.67% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CNC | 0.11% | $30.63B | -20.65% | 0.00% |
KMB | 0.17% | $46.72B | +5.37% | 3.49% |
BBDO | -0.19% | $13.09B | +11.40% | 1.47% |
MOMO | -0.22% | $769.49M | +9.07% | 0.00% |
CAG | -0.23% | $10.98B | -25.07% | 6.03% |
GME | -0.28% | $12.48B | +20.53% | 0.00% |
FRO | 0.31% | $4.10B | -34.52% | 9.86% |
TR | -0.34% | $2.47B | +16.63% | 1.06% |
PDD | 0.41% | $164.90B | -19.30% | 0.00% |
DADA | -0.43% | $528.70M | +7.94% | 0.00% |
KO | 0.44% | $309.61B | +14.96% | 2.73% |
CALM | -0.44% | $5.18B | +63.64% | 6.95% |
BF.A | -0.53% | $16.74B | -26.15% | 2.50% |
KDP | 0.56% | $45.95B | +0.45% | 2.67% |
PRT | 0.60% | $48.42M | +2.31% | 11.27% |
AWK | 0.60% | $28.03B | +7.59% | 2.17% |
PSQH | 0.62% | $89.71M | -47.18% | 0.00% |
AQB | -0.68% | $3.17M | -56.89% | 0.00% |
PPC | 0.69% | $11.56B | +44.37% | 0.00% |
PM | 0.70% | $269.54B | +73.88% | 3.07% |